详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

REALizing and improving management of COPD in China: A prospective observational study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]China Japan Friendship Hosp, Beijing, Peoples R China [2]Chinese Acad Med Sci, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China [3]Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China [4]Peking Union Med Coll Hosp, Beijing, Peoples R China [5]China Med Univ, First Hosp, Shenyang, Peoples R China [6]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [7]Peking Univ Third Hosp, Beijing, Peoples R China [8]Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Natl Clin Res Ctr Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China [9]AstraZeneca China, Shanghai, Peoples R China

出处：

DOI：

ISSN：

关键词： COPD - management COPD - exacerbations Adherence

语种：

WOS：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区呼吸系统

JCR分区：

出版当年[2019]版：

Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 17 最新五年平均[2021-2025] 17.7 出版当年[2019版] 12.339 出版当年五年平均[2015-2019] 11.706 出版前一年[2018版] 11.807 出版后一年[2020版] 16.671

第一作者：

第一作者单位： [1]China Japan Friendship Hosp, Beijing, Peoples R China [2]Chinese Acad Med Sci, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China [3]Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial [2]Validity of COPD diagnoses reported through nationwide health insurance systems in the People's Republic of China [3]Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study [4]Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [5]Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD [6]Enjoying Breathing Program: A National Prospective Study Protocol to Improve Chronic Obstructive Pulmonary Disease Management in Chinese Primary Health Care [7]Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study [8]REALizing and improving management of stable COPD in China: a multi-center, prospective, observational study to realize the current situation of COPD patients in China (REAL) - rationale, study design, and protocol [9]Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China [10]The Intraoperative Adherence to Multimodal Analgesia of Anesthesiologists: A Retrospective Study